Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001178913-25-003941
Filing Date
2025-11-24
Accepted
2025-11-24 07:00:17
Documents
6
Period of Report
2025-11-24

Document Format Files

Seq Description Document Type Size
1 6-K zk2534058.htm 6-K 9239
2 REGISTRANT'S PRESS RELEASE DATED NOVEMBER 24, 2025; exhibit_1.htm EX-99 364009
3 REGISTRANT'S CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF SEPTEMBER exhibit_2.htm EX-99 441209
4 REGISTRANT'S OPERATING AND FINANCIAL REVIEW AS OF SEPTEMBER 30, 2025 AND FOR THE exhibit_3.htm EX-99 253159
5 image0.jpg GRAPHIC 27798
6 image00001.jpg GRAPHIC 36052
  Complete submission text file 0001178913-25-003941.txt   1157042
Mailing Address 2 HAMAAYAN STREET MODI-IN TECHNOLOGY PARK MODI-IN Israel ISRAEL
Business Address 2 HAMAAYAN STREET MODI-IN TECHNOLOGY PARK MODI-IN Israel ISRAEL 972-8-642-9100
BioLineRx Ltd. (Filer) CIK: 0001498403 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-35223 | Film No.: 251509551
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)